OUR PIPELINE

BioInvent is currently running drug projects in development phase, BI-505 and BI-1206, focusing on haematological cancers where the medical need is considered significant. In addition, BioInvent has a number of research stage projects that the company considers promising.

READ MORE

F.I.R.S.T.™

  • Enables combined target and drug discovery
  • No prior knowledge of the target is required
  • Allows for direct functional screening
  • Identifies disease targets that:
    • have a higher level of protein expression without a corresponding increase in mRNA expression
    • include post-translational modifications
    • are generated through protein-protein interactions

READ MORE

Press Releases

MEET US

18 Nov, 26th EORTC-NCI-AACR Symposium, Barcelona, Spain
6-9 Dec, 56th ASH Annual Meeting, San Francisco, USA

 

INVESTOR PRESENTATION

11 Nov, Investor Forum Redeye, Sthlm (Swedish)

SEK